The public-private partnership ‘Innovative Health Initiative’ (IHI), built on 14 years of experience from the previous ‘Innovative Medicines Initiative’(IMI), expands its scope, focusing less directly on pharmaceuticals and more broadly on health care.
The new Innovative Health Initiative (IHI) is meant to pave the way for better innovation to tackle today’s health issues and what we might face in the future.
While the previous ‘Innovative Medicines Initiative’ (IMI) had a narrower focus on the pharmaceutical industry, the IHI has taken a broader range of industries under its wing, such as biopharmaceutical, biotech, and medical technology sectors.
The Council approved the Commission proposal to create the public-private partnership IHI in November 2021.
Half of the €2.4 billion going into the IHI from 2021-2027 stems from Horizon Europe, the EU’s framework programme for research and innovation. €1 billion will come from IHI industry partners, and the last €200 million will be funded by various life science industries or associations as contributing partners.
“IHI strives to be more inclusive by integrating sectors well beyond the pharmaceutical industry, including diagnostics, medical imaging, medical devices and everything digital,” said Pierre Meulien, the IHI executive director, at the launch event on Wednesday (26 January).
He added that this is necessary to both accelerate innovation for the benefit of European citizens and to help maintain the industrial competitiveness of the European healthcare industry sector.
IHI hopes to expand involvement
Compared to its predecessor, one of the most significant changes is the governing board of the IHI that reflects its broader scope, representing a more significant proportion of industry sectors and European Commission representatives from four different general directorates – DG RTD DG GROW, DG SANTE and DG CONNECT.
Along with the new board comes a recent Strategic Research and Innovation Agenda, which will be implemented with the help of the Science and Innovation panel, providing the governing board with scientific-based advice.
While SMEs were represented in the IMI, the goal in the IHI is to increase their number. In terms of geography, IHI director Pierre Meulien also wants to see an increase in the involvement of Eastern European countries.
“I’ve always maintained that there’s no reason why their involvement should be lower than from other parts of Europe. And we will use as many mechanisms as we can to make IHI attractive to all Europeans,” he said during the presentation.
Lastly, the amount of patient involvement in IHI increases compared to the IMI. Based on an IMI project regarding patient involvement, the IHI is confident of its capabilities on this part and wants to develop a patient involvement strategy in 2022.
Thrilled partners
“By joining forces, we can and will deliver more for patients and society,” said Nathalie Moll, director-general of the EU’s pharmaceutical association (EFPIA).
In particular, new partners who were not part of the previous IMI praise the changes made in the IHI, highlighting that there is finally a public-private partnership with a generally broader approach across more fields.
“If we’re able to do this, I think we will better understand what we need to do to have a much stronger system across Europe, a much more resilient system, which will hopefully find solutions to improving access to treatment for patients,” said Serge Bernasconi, chief executive officer at MedTech Europe, the EU’s trade organisation for medical devices businesses.
“The starting point is super solid. The ambition is extremely high. And I think the expectations are high, including (…) the setup, which will allow us to work much better with patients and doctors,” concluded Jean-Eric Paquet, Director-General at the Commission’s DG Research and Innovation.
[Edited by Gerardo Fortuna/ Alice Taylor]
